Enzon Reports First Quarter 2012 Results
FOR: ENZON PHARMACEUTICALS, INC.
MAY 2, 2012 - 08:00 ET
PISCATAWAY, NJ--(Marketwire - May 2, 2012) - Enzon Pharmaceuticals, Inc. (
Summary of Financial Results
Royalty revenue for the three months ended March 31, 2012 was $10.3 million, as compared to $11.8 million for the three months ended March 31, 2011. Royalties on PEGINTRON®, marketed by Merck & Co., Inc., continued to comprise the majority of the Company's royalty revenue, and a reported decline in foreign sales of PEGINTRON was largely accountable for the decrease in royalty revenue.
Research and Development
The Company's pipeline research and development expenses were $6.9 million for the three months ended March 31, 2012, as compared to $10.5 million for the three months ended March 31, 2011. The pipeline consists of the following clinical programs: PEG-SN38 and mRNA antagonists targeting Hypoxia-Inducible Factor-1α (HIF-1α), Survivin and the Androgen Receptor (AR). In addition, the Company has other novel LNA targets in various stages of preclinical research. Clinical expenses for the first quarter of 2012 declined primarily due to a $2.1 million reduction in salaries and benefits expenses as a result of the restructuring implemented during the fourth quarter of 2011. In addition, Enzon completed enrollment in both of the Company's Phase II clinical trials of PEG-SN38, as well as Phase I clinical trials for HIF-1α and Survivin.
General and Administrative
General and administrative expenses decreased approximately 28% to $3.7 million for the three months ended March 31, 2012 from $5.1 million for the three months ended March 31, 2011. The decline in 2012 from 2011 was largely the result of several restructuring programs implemented over the past year, as well as the Company's on-going cost containment efforts.
Cash and Investments
Total cash reserves, which consist of cash, cash equivalents and marketable securities, were $318.7 million as of March 31, 2012, as compared to $323.3 million as of December 31, 2011. The decrease was primarily attributable to $3.75 million of outstanding notes payable repurchased during the first quarter of 2012.
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Enzon's drug-development programs utilize two platforms -- Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four compounds in human clinical development and multiple novel mRNA antagonists in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology. Further information about Enzon and this press release can be found on the Company's website at www.enzon.com.
This press release contains, or may contain, forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements that are purely historical, are forward-looking statements, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions.
Such forward-looking statements are based upon management's present expectations, objectives, anticipation, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements. A more detailed discussion of these and other factors that could affect results is contained in Enzon's filings with the U.S. Securities and Exchange Commission, including Enzon's Annual Report on Form 10-K for the year ended December 31, 2011. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.
|Enzon Pharmaceuticals, Inc. and Subsidiaries|
|Condensed Consolidated Statements of Comprehensive (Loss) Income|
|(Unaudited; In thousands, except per share amounts)|
|Three months ended|
|Sale of in-process research and development||-||5,000|
|Contract research and development||103||1,094|
|Research and development - pipeline||6,914||10,548|
|Research and development - specialty and contracted services||85||647|
|General and administrative||3,675||5,086|
|General and administrative - contracted services||-||58|
|Total Operating Expenses||10,637||16,698|
|Operating (Loss) Income||(36||)||1,324|
|Other Income (Expense):|
|Investment income, net||478||459|
|Total Other Expense||(1,035||)||(893||)|
|Loss before income tax expense||(1,071||)||431|
|Income tax expense||-||-|
|Net (Loss) Income||$||(1,071||)||$||431|
|(Loss) earnings per common share - basic and diluted||$||(0.02||)||$||0.01|
|Weighted-average shares - basic||48,293||58,002|
|Weighted-average shares - diluted||48,293||58,736|
|Other Comprehensive Income (Loss):|
|Available-for-sale marketable securities:|
|Unrealized holding gains (losses) arising during period||$||537||$||(125||)|
|Reclassification adjustment for realized losses (gains) on sales included in net (loss) income||
|Total Other Comprehensive Income (Loss)||572||(147||)|
|Comprehensive (Loss) Income||$||(499||)||$||284|
|Enzon Pharmaceuticals, Inc. and Subsidiaries|
|Condensed Consolidated Balance Sheets|
|(Unaudited; In thousands)|
|March 31,||December 31,|
|Cash and cash equivalents||$||46,214||$||104,324|
|Other current assets||2,456||2,749|
|Total current assets||127,150||165,261|
|Property and equipment, net||15,506||16,802|
|Liabilities and Stockholders' Equity|
|Accrued expenses and other current liabilities||11,072||13,692|
|Total current liabilities||12,970||15,264|
|Total Stockholders' Equity||$||197,146||$||197,181|
|Total Liabilities and Stockholders' Equity||$||336,946||$||343,209|
FOR FURTHER INFORMATION PLEASE CONTACT: